報價延遲最少15分鐘:2025/06/01 17:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.08 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.29/-1.31
|
|
企業價值
268.87M
|
| 資產負債 |
|
每股賬面淨值
-1.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.60M
|
|
每股收益
0.58
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 17:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. |